A data analytics approach for rational design of nanomedicines with programmable drug release

Thumbnail Image
Date
2019-05-06
Authors
Mullis, Adam
Broderick, Scott
Binnebose, Andrea
Peroutka-Bigus, Nathan
Bellaire, Bryan
Rajan, Krishna
Narasimhan, Balaji
Major Professor
Advisor
Committee Member
Journal Title
Journal ISSN
Volume Title
Publisher
Authors
Person
Narasimhan, Balaji
Distinguished Professor
Research Projects
Organizational Units
Organizational Unit
Chemical and Biological Engineering

The function of the Department of Chemical and Biological Engineering has been to prepare students for the study and application of chemistry in industry. This focus has included preparation for employment in various industries as well as the development, design, and operation of equipment and processes within industry.Through the CBE Department, Iowa State University is nationally recognized for its initiatives in bioinformatics, biomaterials, bioproducts, metabolic/tissue engineering, multiphase computational fluid dynamics, advanced polymeric materials and nanostructured materials.

History
The Department of Chemical Engineering was founded in 1913 under the Department of Physics and Illuminating Engineering. From 1915 to 1931 it was jointly administered by the Divisions of Industrial Science and Engineering, and from 1931 onward it has been under the Division/College of Engineering. In 1928 it merged with Mining Engineering, and from 1973–1979 it merged with Nuclear Engineering. It became Chemical and Biological Engineering in 2005.

Dates of Existence
1913 - present

Historical Names

  • Department of Chemical Engineering (1913–1928)
  • Department of Chemical and Mining Engineering (1928–1957)
  • Department of Chemical Engineering (1957–1973, 1979–2005)
    • Department of Chemical and Biological Engineering (2005–present)

    Related Units

Journal Issue
Is Version Of
Versions
Series
Department
Chemical and Biological EngineeringMicrobiologyNanovaccine Institute
Abstract

Drug delivery vehicles can improve the functional efficacy of existing antimicrobial therapies by improving biodistribution and targeting. A critical property of such nanomedicine formulations is their ability to control the release kinetics of their payloads. The combination of (and interactions between) polymer, drug, and nanoparticle properties gives rise to nonlinear behavioral relationships and a large data space. These factors complicate both first-principles modeling and screening of nanomedicine formulations. Predictive analytics may offer a more efficient approach toward rational design of nanomedicines by identifying key descriptors and correlating them to nanoparticle release behavior. In this work, antibiotic release kinetics data were generated from polyanhydride nanoparticle formulations with varying copolymer compositions, encapsulated drug type, and drug loading. Four antibiotics, doxycycline, rifampicin, chloramphenicol, and pyrazinamide, were used. Linear manifold learning methods were used to relate drug release properties with polymer, drug, and nanoparticle properties, and key descriptors were identified that are highly correlated with release properties. However, these linear methods could not predict release behavior. Non-linear multivariate modeling based on graph theory was then used to deconvolute the governing relationships between these properties, and predictive models were generated to rapidly screen lead nanomedicine formulations with desirable release properties with minimal nanoparticle characterization. Release kinetics predictions of two drugs containing atoms not included in the model showed good agreement with experimental results, validating the model and indicating its potential to virtually explore new polymer and drug pairs not included in training data set. The models were shown to be robust after inclusion of these new formulations in that the new inclusions did not significantly change model regression. This approach provides the first steps towards development of a framework that can be used to rationally design nanomedicine formulations by selecting the appropriate carrier for a drug payload to program desirable release kinetics.

Comments

This document is the unedited Authors version of a Submitted Work that was subsequently accepted for publication in Molecular Pharmaceutics, copyright American Chemical Society after peer review. To access the final edited and published work see DOI: 10.1021/acs.molpharmaceut.8b01272. Posted with permission.

Description
Keywords
Citation
DOI
Copyright
Tue Jan 01 00:00:00 UTC 2019
Collections